Redefining PRRT: Advancing EBTATE Towards a New Standard of Care for Gastroenteropancreatic Neuroendocrine Tumours

9:30 am - Thursday 3rd December 2026

  • Presenting the latest clinical data supporting EBTATE, including encouraging efficacy, safety and durability outcomes as the programme advances towards pivotal Phase III evaluation
  • Examining how enhanced tumour retention and albumin-binding technology enables meaningful therapeutic responses with substantially lower administered radioactivity and without amino acid co-infusion
  • Comparing the clinical and practical implications of next-generation PRRT against existing treatment paradigms to understand where meaningful differentiation can be achieved